Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies.

Karapanagiotou EM, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C, Newbold K, Gore ME, Larkin J, Syrigos KN, Coffey M, Thompson B, Mettinger K, Vile RG, Pandha HS, Hall GD, Melcher AA, Chester J, Harrington KJ.

Clin Cancer Res. 2012 Apr 1;18(7):2080-9. doi: 10.1158/1078-0432.CCR-11-2181. Epub 2012 Feb 7.

2.

A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer.

Lolkema MP, Arkenau HT, Harrington K, Roxburgh P, Morrison R, Roulstone V, Twigger K, Coffey M, Mettinger K, Gill G, Evans TR, de Bono JS.

Clin Cancer Res. 2011 Feb 1;17(3):581-8. doi: 10.1158/1078-0432.CCR-10-2159. Epub 2010 Nov 24.

3.

REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer.

Comins C, Spicer J, Protheroe A, Roulstone V, Twigger K, White CM, Vile R, Melcher A, Coffey MC, Mettinger KL, Nuovo G, Cohn DE, Phelps M, Harrington KJ, Pandha HS.

Clin Cancer Res. 2010 Nov 15;16(22):5564-72. doi: 10.1158/1078-0432.CCR-10-1233. Epub 2010 Oct 6.

4.

Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors.

Gollamudi R, Ghalib MH, Desai KK, Chaudhary I, Wong B, Einstein M, Coffey M, Gill GM, Mettinger K, Mariadason JM, Mani S, Goel S.

Invest New Drugs. 2010 Oct;28(5):641-9. doi: 10.1007/s10637-009-9279-8. Epub 2009 Jul 2.

5.

Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer.

Chedid S, Rivera E, Frye DK, Ibrahim N, Esteva F, Valero V, Hortobagyi G, Mettinger KL, Cristofanilli M.

Cancer Chemother Pharmacol. 2006 Apr;57(4):540-4. Epub 2005 Sep 29.

PMID:
16193332
6.

A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer.

Baka S, Ranson M, Lorigan P, Danson S, Linton K, Hoogendam I, Mettinger K, Thatcher N.

Eur J Cancer. 2005 Jul;41(11):1547-50.

PMID:
16026691
7.

Phase II trial of oral rubitecan in previously treated pancreatic cancer patients.

Burris HA 3rd, Rivkin S, Reynolds R, Harris J, Wax A, Gerstein H, Mettinger KL, Staddon A.

Oncologist. 2005 Mar;10(3):183-90.

8.

Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors.

de Jonge MJ, Droz JP, Paz-Ares L, van Oosterom AT, de Wit R, Chollet P, Baron B, Lacombe D, Mettinger K, Fumoleau P; EORTC-New Drug Development Group/New Drug Development Program.

Invest New Drugs. 2004 Aug;22(3):329-33.

PMID:
15122081
9.

Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma.

Tulpule A, Groopman J, Saville MW, Harrington W Jr, Friedman-Kien A, Espina BM, Garces C, Mantelle L, Mettinger K, Scadden DT, Gill PS.

Cancer. 2002 Jul 1;95(1):147-54.

10.

Randomized trial of Cervene, a kappa receptor-selective opioid antagonist, in acute ischemic stroke.

Clark WM, Coull BM, Karukin M, Hendin B, Kelley R, Rosing H, Zachariah S, Winograd M, Raps E, Walshe T, Singer S, Mettinger KL.

J Stroke Cerebrovasc Dis. 1996 Sep-Oct;6(1):35-40.

PMID:
17894963
11.

Effects of Alzene and tacrine on water maze reference and working memory function in medial septal-lesioned rats.

Riekkinen P Jr, Mettinger KL, Karukin M, Riekkinen M.

Brain Res. 1996 Apr 1;714(1-2):118-24.

PMID:
8861616
12.

The antitumoral effect of the immunomodulator AS101 and paclitaxel (Taxol) in a murine model of lung adenocarcinoma.

Kalechman Y, Shani A, Dovrat S, Whisnant JK, Mettinger K, Albeck M, Sredni B.

J Immunol. 1996 Feb 1;156(3):1101-9.

PMID:
8557985
13.

The protective role of the immunomodulator AS101 against chemotherapy-induced alopecia studies on human and animal models.

Sredni B, Xu RH, Albeck M, Gafter U, Gal R, Shani A, Tichler T, Shapira J, Bruderman I, Catane R, Kaufman B, Whisnant JK, Mettinger KL, Kalechman Y.

Int J Cancer. 1996 Jan 3;65(1):97-103.

14.

Thrombolytic intervention and its effect on mortality in acute myocardium infarction.

Mettinger KL.

Heart Lung. 1990 Mar;19(2):213-5. No abstract available.

PMID:
2180864
15.
16.
17.

HLA and ischemic cerebrovascular disease. A study of patients with stroke before the age of 56.

Smith CI, Hammarström L, Kjellin KG, Mettinger KL, Sidén A, Söderström CE.

Acta Neurol (Napoli). 1983 Aug;5(4):268-71. No abstract available.

PMID:
6650244
18.

Enteric-coated aspirin and cyclooxygenase inhibition.

Svensson J, Mettinger KL, Blombäck M.

Thromb Res. 1983 Jan 1;29(1):99-102. No abstract available.

PMID:
6404001
23.
24.
25.

Fibromuscular dysplasia and the brain. II. Current concept of the disease.

Mettinger KL.

Stroke. 1982 Jan-Feb;13(1):53-8. Review.

PMID:
7039003
26.

Shortened megakaryocyte-platelet regeneration time in patients with ischemic cerebrovascular disease.

Hamberg M, Svensson J, Blombäck M, Mettinger KL.

Thromb Res. 1981 Mar 15;21(6):675-9. No abstract available.

PMID:
7268705
27.

Computed tomography and CSF spectrophotometry. Diagnosis and prognosis in 300 patients with cerebrovascular disease.

Söderström CE, Ericson K, Mettinger KL, Olivecrona H.

Scand J Rehabil Med. 1981;13(2-3):65-71.

PMID:
7345568
28.

[Anti-coagulant therapy in TIA and cerebral infarct].

Gudmundsson G, Kjellin K, Mettinger KL, Sidén A, Sjöström L, Söderström CE.

Lakartidningen. 1980 Dec 24;77(52):4956-8. Swedish. No abstract available.

PMID:
7010030
29.

[Multicenter studies in the USA and Canada: thrombocyte function inhibitor in ischemic cerebrovascular diseases].

Blombäck M, Mettinger KL.

Lakartidningen. 1980 Jan 30;77(5):320-2. Swedish. No abstract available.

PMID:
7366288
30.

Isoelectric focusing of cerebrospinal fluid proteins in ischemic cerebrovascular disease.

Gudmundsson G, Kjellin KG, Mettinger KL, Sidén A, Söderström CE.

J Neurol. 1980;222(4):227-34.

PMID:
6154781
31.

Factor VIII related antigen, antithrombin III, spontaneous platelet aggregation and plasminogen activator in ischemic cerebrovascular disease: a study of stroke before 55.

Mettinger KL, Nyman D, Kjellin KG, Sidén A, Söderström CE.

J Neurol Sci. 1979 Mar;41(1):31-8. No abstract available.

PMID:
438842
32.

[Dicoumarol or warfarin? A pharmacologic, biopharmacolocic and clinical comparison].

Kjellin K, Källstrand G, Mettinger KL, Sidén A, Söderström CE.

Lakartidningen. 1978 Aug 30;75(35):2971-73. Swedish. No abstract available.

PMID:
80521
33.

[Intracerebral hemorrhages (1): Clinical course, examination procedures and treatment principles].

Kjellin K, Mettinger KL, Sidén A, Sjöström L, Söderström CE.

Lakartidningen. 1978 Jul 12;75(28-29):2636-9. Swedish. No abstract available.

PMID:
682736
34.

Dyslipoproteinemia in patients with ischemic cerebro-vascular disease: a study of stroke before the age of 55.

Rössner S, Kjellin KG, Mettinger KL, Sidén A, Söderström CE.

Atherosclerosis. 1978 Jul;30(3):199-209.

PMID:
209803
35.

Gamma scanning of atherosclerotic plaques in carotid arteries.

Mettinger KL, Larsson S.

Lancet. 1978 Jun 10;1(8076):1267. No abstract available.

PMID:
78035
36.

Pathogenetic profile of TIA before 55. A three-year investigation.

Mettinger KL, Söderström CE.

J Neurol Sci. 1978 May;36(3):341-8.

PMID:
681966
37.

Normal serum-cholesterol but low H.D.L.-cholesterol concentration in young patients with ischaemic cerebrovascular disease.

Rössner S, Kjellin KG, Mettinger KL, Sidén A, Söderström CE.

Lancet. 1978 Mar 18;1(8064):577-9.

PMID:
76122
38.

Detection of atherosclerotic plaques in carotid arteries by the use of 123I-fibrinogen.

Mettinger KL, Larsson S, Ericson K, Casseborn S.

Lancet. 1978 Feb 4;1(8058):242-4.

PMID:
74666
39.

[Ischemic cerebrovascular lesions (2). Survey of principles of examination and treatment at the Neurological Department of Karolinska hospital].

Kjellin K, Mettinger KL, Sidén A, Söderström CE.

Lakartidningen. 1976 Nov 10;73(46):3973-4. Swedish. No abstract available.

PMID:
979465

Supplemental Content

Loading ...
Support Center